Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Famciclovir effect on EBV shedding in saliva of MS patients on natalizumab
2019-000169-19Phase 2Unknown
- Sponsor
- Queen Mary University of London
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of famciclovir in Epstein-Barr virus infection and multiple sclerosis (MS), sponsored by Queen Mary University of London. Primary endpoint: Suppression of EBV shedding in saliva. Status: unknown.
02
Drugs
famciclovir
03
Conditions
Epstein-Barr virus infectionmultiple sclerosis (MS)
Beyond the preview
Go deeper on 2019-000169-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000169-19.